louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03744936: Decision Aids for Patients With Nonvalvular Chronic Atrial Fibrillation (DA4AFib)
Official title: Decision Aids for Patients With Nonvalvular Chronic Atrial Fibrillation (DA4AFib)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atrial Fibrillation
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: American Heart Association
First posted: 2018-11-19
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Encounters of subjects scheduled for AF (Atrial Fibrillation) treatment will be observed (by a study team member and/or using a video recording device) at Mayo Clinic Rochester and may be observed at Mayo Clinic Health System sites in Minnesota.

Brief summary: The researchers are observing subject and clinician interaction in order to develop future education materials that will help patients and clinicians discuss atrial fibrillation and options to treat it.


Eligibility criteria: 1. Must be 18 or older
2. Must have an appointment for Atrial Fibrillation
3. Must not have dementia
4. Must not have severe hearing or vision impairment Patients will be given a written consent Guests that accompany patients will be given an oral consent KER unit PAG members will be given an oral consent

Primary outcomes:
measure: Interview Process
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Victor M Montori
role: PRINCIPAL_INVESTIGATOR
References:
citation: Jones AE, McCarty MM, Cameron KA, Cavanaugh KL, Steinberg BA, Passman R, Kansal P, Guzman A, Chen E, Zhong L, Fagerlin A, Hargraves I, Montori VM, Brito JP, Noseworthy PA, Ozanne EM. Development of Complementary Encounter and Patient Decision Aids for Shared Decision Making about Stroke Prevention in Atrial Fibrillation. MDM Policy Pract. 2023 Jun 21;8(1):23814683231178033. doi: 10.1177/23814683231178033. eCollection 2023 Jan-Jun.
Clinical trial NCT03227536: Asphyxia at Birth : Causes and Neonatal Outcome
Official title: Asphyxia at Birth : Evolution of Birth Asphyxia Rate, Etiologies and Neonatal Outcome From 2000 to 2016
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neonatal Asphyxia
Keywords: Neonatal asphyxia
neonatal acidosis
fetal ECG
umbilical cord acid-base status
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2017-07-24
Enrollment: 61448
Sex: ALL
Maximum age (years): 1
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All births at the maternity ward of the hospital Femme-Mère-Enfant from 1st of january 2000 to 31 december 2016

Brief summary: This is an historic cohort study based on the birth and delivery register of the HFME maternity ward. This study aim at understanding the evolution of asphyxia at birth, at all gestational ages, identifying causes and describing neonatal outcomes since 2000, when a second line strategy for foetal surveillance (fetal ECG) and systematic umbilical acid-gas cord blood were introduced in our maternity ward.

The investigator's hypothesis was that the neonatal asphyxia decrease could be due to 3 main factors including second line strategy introduction, systematic umbilical cord acid-base implementation and improvement in antenatal risk factor screening for asphyxia. The investigator's second hypothesis was that neonatal prognosis in neonates with acidosis was improved with systematic early after birth EEG evaluation, allowing early treatment and surveillance.


Eligibility criteria: Inclusion Criteria:

* All births at the maternity ward of the hospital Femme-Mère-Enfant from 1st of january 2000 to 31 december 2016

Exclusion Criteria:

* Infants born after medical pregnancy termination and born out of the hospital and secondarily hospitalized in our department will be excluded

Primary outcomes:
measure: Rate of Neonatal asphyxia
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Department of obstetrics, Femme Mère Enfant Hospital
Study officials:
affiliation: Hospices Civils de Lyon
name: Muriel DORET, Pr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02478736: Preoperative Transcranial Doppler as a Predictor for Delirium Following On-pump Cardiac Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Postoperative Delirium After On-pump Cardiac Surgery
Keywords: postoperative delirium
on-pump cardiac surgery
cerebral oximetry
cerebral blood flow velosity
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2015-06-23
Enrollment: 175
Sex: ALL
Minimum age (years): 60
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients undergoing on-pump cardiac surgery

Brief summary: Postoperative delirium is an important problem in patients undergoing major cardiac surgery and associated with more complicated hospital course, increased hospital length of stay and total postoperative cost. A study shows that a low preoperative cerebral oximetry (rSO2) is associated with postoperative delirium after on-pump cardiac surgery. Another study showed that patients who underwent cardiac surgery with reduced cerebral blood flow (CBF) velocity in the left middle cerebral artery (MCA) preoperatively are at greater risk for postoperative cognitive dysfunction (POCD). Therefore, the investigators hypothesize that lower perioperative rSO2 and reduced preoperative mean flow velocity (MFV) of MCA are good predictors of the postoperative delirium in the patients undergoing the on-pump cardiac surgery.


Eligibility criteria: Inclusion Criteria:

1. Patients in the study will be 60 or older undergoing elective major on-pump cardiac surgery

Exclusion Criteria:

1. No communication possible due to a language barrier or deafness
2. Patients diagnosed with neurocognitive disorders or psychiatric diseases (MMSE or Geriatric Depression Scale cannot be checked before surgery)
3. Patients with unstable hemodynamics or intubated before surgery
4. Patients diagnosed with significant (≥ 50%) intracranial stenosis confirmed by CT angiography or MR angiography
5. Patients diagnosed with stroke, TIA or neurologic diseases (e.g. Parkinson's disease, epilepsy, dementia, or taking psychiatric medications d/t psychiatric disorders)

Primary outcomes:
measure: the predictive power of perioperative MFV of MCA regarding postoperative delirium
timeFrame: 7 days from postoperation
measure: the predictive power of periopertiver rSO2 values regarding postoperative delirium
timeFrame: 7 days from postoperation
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Yonsei University College of Medicine
Study officials:
References:
Clinical trial NCT06582836: A Comparative Assessment of Post Extraction Pain in Orthodontic Patients to Evaluate the Effects of Early Engagement of Tooth with Orthodontic Wires. a Single Center Randomized Clinical Trial (RCT)
Official title: A Comparative Assessment of Post Extraction Pain in Orthodontic Patients to Evaluate the Effects of Early Engagement of Tooth with Orthodontic Wires. a Single Center Randomized Clinical Trial (RCT)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Orthodontic Extraction
Orthodontic Treatment
Orthodontic Treatment Via Premolar Extraction
Lead sponsor: Universiti Sains Malaysia
Sponsor class: OTHER
First posted: 2024-09-03
Enrollment: 44
Sex: ALL
Minimum age (years): 14
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The goal of this clinical trial is to determine if the timing of tooth extractions (before or after initial orthodontic treatment) affects pain levels in patients who need bilateral extractions of first premolars in the upper jaw. The participants in this study are patients who require these extractions as part of their orthodontic treatment.

The main questions it aims to answer are:

1. Does extracting teeth before starting orthodontic treatment result in different pain levels compared to extracting teeth after alignment?
2. How do pain levels change over time after the extractions in each group?

Researchers will compare Group A (patients who have extractions before orthodontic treatment) to Group B (patients who have extractions after initial alignment) to see if the timing of the extractions affects pain levels.

Participants will:

Undergo tooth extractions either before or after initial alignment based on their group.

Rate their pain on an 11-point numerical rating scale at various times (2, 4, 8, 12, and 24 hours after extraction, and then daily for a week).


Eligibility criteria: Inclusion Criteria:

* 12 to 18-year-old orthodontic patients needing bilaterally symmetrical extractions of first premolars as a part of orthodontic treatment. Angles class I with moderate to severe crowding cases, bimaxillary proclination, and Angles class II division 1 were included.

Exclusion Criteria:

* Patients with poor oral hygiene, carious or missing premolars, multiple missing teeth, systemic diseases, periodontitis or patients on analgesics (NSAIDs, and corticosteroids) were excluded from the study.

Primary outcomes:
measure: A comparative assessment of post extraction pain in orthodontic patients to evaluate the effects of early engagement of tooth with orthodontic wires.
timeFrame: 2.6 years
Secondary outcomes:
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: Baqai Medical University
state: Sind
Study officials:
References:
Clinical trial NCT00387036: Exercise Study in Patient With Chronic Obstructive Pulmonary Disease (0000-036)
Official title: A Multicenter, Double-Blind Placebo-Controlled Crossover Study to Investigate the Effects of an Inhaled Corticosteroid on Cardiopulmonary Exercise Parameters in Patients With Chronic Obstructive Pulmonary Disease
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2006-10-12
Enrollment: 12
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To test the effect of the research study drug, inhaled fluticasone on lung function in exercising patients with Chronic Obstructive Pulmonary Disease (COPD).


Eligibility criteria: Inclusion Criteria:

* 40 years and older
* Clinical diagnosis of COPD for greater than one year
* History of cigarette smoking

Exclusion Criteria:

* Other lung diseases (not including COPD), such as asthma
* A condition that could interfere with your ability to perform exercise tests

Primary outcomes:
measure: Standardized Dyspnea Score at Isotime During Exercise
timeFrame: 2 Weeks
Secondary outcomes:
measure: Exercise Endurance Time
timeFrame: 2 Weeks
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Guenette JA, Raghavan N, Harris-McAllister V, Preston ME, Webb KA, O'Donnell DE. Effect of adjunct fluticasone propionate on airway physiology during rest and exercise in COPD. Respir Med. 2011 Dec;105(12):1836-45. doi: 10.1016/j.rmed.2011.08.021. Epub 2011 Sep 13.
Clinical trial NCT05706636: T Central Memory Cells in Early Localized Non-Segmental Vitiligo
Official title: T Central Memory Cells in Early Localized Non-Segmental Vitiligo and the Effect of Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vitiligo
Keywords: early localized vitiligo
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-01-31
Enrollment: 22
Sex: ALL
Minimum age (years): 12
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Assessing the level of circulating TCMs (cluster of differentiation (CD) 8+, CD3+,C- chemokine receptor (CCR)7, cluster of differentiation 45 receptor (CD45R) cells) in early localized vitiligo cases prior to treatment and after treatment in comparison to healthy controls. This, in turn, would provide insights regarding the role of TCMs in vitiligo and the role of early treatment in halting disease progression and autoimmune memory formation that accounts for high recurrence rate of vitiligo

Detailed description: Assessing the level of circulating TCMs (CD8+ CD3+ CCR7+ CD45RO+ cells) in early localized vitiligo cases where samples will be processed and stained for CD8, CD3, CCR7, . CCR7, CD45R. Multi-parametric flow cytometry will be used to quantify CD3+ve, CD8+ve, CCR7+ve, CD45RO+ve TCM cells percentage, which will be expressed as a percentage from the total lymphocyte gate. This will be done prior to treatment and after treatment and will be compared to healthy controls.

Eligibility criteria: Inclusion Criteria:

- Subjects with vitiligo localized to one anatomical area, of ≤ 6 months' duration

Exclusion Criteria:

* Patients who received treatment of any type (topical or systemic) within the last 3 months

Primary outcomes:
measure: comparing level of circulating central memory T cells (TCM) in early localized vitiligo cases to healthy controls
timeFrame: 6 months
measure: percent change in the level of circulating central memory T cells (TCM) in early localized vitiligo cases after treatment
timeFrame: 6 months
measure: comparing percent change in the level of circulating central memory T cells (TCM) in early localized vitiligo cases after treatment in those receiving systemic treatment to those receiving only topical treatment
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo university hospitals, dermatology outpatient clinic
Study officials:
affiliation: Cairo University
name: Samia Esmat, MD
role: STUDY_CHAIR
References:
Clinical trial NCT02290236: Monitored Saturation Post-ICU
Official title: Monitored Saturation Post-ICU; Correlation to Charted Saturation, Pre-intensive Care Unit Obstructive Sleep Apnea and Outcome
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Sleep Apnea, Obstructive
Respiratory Insufficiency
Lead sponsor: Karolinska University Hospital
Sponsor class: OTHER
First posted: 2014-11-14
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients that are discharged from the intensive care unit

Brief summary: The overall aim with this project is to describe the correlation between measured and charted saturation after intensive care and also describe the saturation-pattern in these patients. The investigators will also correlate post-ICU desaturations measured as oxygen denaturation index and complications to pre-ICU obstructive sleep apnea and the STOP BANG screening questionnaire.


Eligibility criteria: Inclusion Criteria:

* \>18 years of age.
* Admitted to the Central Intensive Care Unit (CIVA)
* Signed informed conscent by the patient or a relative

Exclusion Criteria:

-

Primary outcomes:
measure: Oxygen desaturation index (ODI)
timeFrame: Days
Secondary outcomes:
measure: STOP Bang screening questionnaire
timeFrame: Days
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Department of Anesthesiology, Surgical Services and Intensive Care Medicine, Karolinska University Hospital, Solna
Study officials:
affiliation: Karolinska University Hospital and Karolinska Institutet
name: Malin Jonsson Fagerlund, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06562036: Efficacy of Milrinone With Sildenafil in Persistent Pulmonary Hypertension in Children
Official title: Efficacy of Milrinone Plus Sildenafil in the Treatment of Neonates With Persistent Pulmonary Hypertension: A Single-Center, Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Persistent Pulmonary Hypertension of the Newborn
Lead sponsor: RESnTEC, Institute of Research
Sponsor class: OTHER
First posted: 2024-08-20
Enrollment: 42
Sex: ALL
Minimum age (years): 1
Maximum age (years): 28
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Neonates with persistent pulmonary hypertension (PPH) should be administered inhaled nitric oxide (iNO) and extracorporeal membrane oxygenation (ECMO), but these are not available in most resource-constrained settings like ours. This study was planned to compare the outcomes of Milrinone plus Sildenafil versus Sildenafil alone in the treatment of PPH in neonates.


Eligibility criteria: Inclusion Criteria:

* Patients of either gender
* Aged between 1-28 days
* Birth weight above 2000 grams
* Diagnosed with persistent pulmonary hypertension (as per echocardiography)

Exclusion Criteria:

* Neonates having congenital heart defects (CHDs)
* Congenital diaphragmatic hernia
* Lung anomalies
* History of any surgical intervention

Primary outcomes:
measure: Change in pulmonary artery systolic pressure
timeFrame: 72 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Multan
country: Pakistan
facility: Children's Hospital and institute of Child Health
state: Punjab
Study officials:
affiliation: Children's Hospital and institute of Child Health Multan, Punjab, Pakistan
name: Muhammad Awais, FCPS
role: PRINCIPAL_INVESTIGATOR
affiliation: Children's Hospital and institute of Child Health Multan, Punjab, Pakistan
name: Abdur Rehman, FCPS
role: STUDY_DIRECTOR
References:
Clinical trial NCT02647736: Copeptin in Normal- to Hyperosmolar States
Official title: Kinetics of Copeptin in Healthy Volunteers - a Prospective International Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Copeptin Blood Values
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2016-01-06
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: Kinetics of Copeptin in response to osmotic alterations in healthy volunteers

Detailed description: Construction of the standard area of copeptin release in the normo- and hyperosmolar state and its half-life based on ist decline during hypoosmotic Suppression in healthy volunteers.

Eligibility criteria: Inclusion Criteria:

* Minimum Age 18
* no severe comorbidities
* no medication (except contraceptives)
* baseline sodium Level 135-145mmol/l
* euvolemic status

Exclusion Criteria:

* history of heart failure
* liver cirrhosis
* kidney disease (GFR \<60ml/min)
* anemia
* uncontrolled Hypertension
* pregnancy
* Diabetes mellitus
* BMI \>28kg/m2
* other severe disease

Primary outcomes:
measure: Physiological relationship between Serum osmolality and Plasma copeptin release.
timeFrame: beginning and end of protocol, up to 8 hours
measure: Half life of Copeptin
timeFrame: beginning and end of protocol, up to 8 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Würzburg
country: Germany
facility: University Hospital Würzburg
city: Basel
country: Switzerland
facility: University hospital Basel
Study officials:
affiliation: University Hospital, Basel, Switzerland
name: Mirjam Christ-Crain, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Sailer CO, Refardt J, Blum CA, Schnyder I, Molina-Tijeras JA, Fenske W, Christ-Crain M. Validity of different copeptin assays in the differential diagnosis of the polyuria-polydipsia syndrome. Sci Rep. 2021 May 12;11(1):10104. doi: 10.1038/s41598-021-89505-9.
citation: Fenske WK, Schnyder I, Koch G, Walti C, Pfister M, Kopp P, Fassnacht M, Strauss K, Christ-Crain M. Release and Decay Kinetics of Copeptin vs AVP in Response to Osmotic Alterations in Healthy Volunteers. J Clin Endocrinol Metab. 2018 Feb 1;103(2):505-513. doi: 10.1210/jc.2017-01891.
Clinical trial NCT01560936: Surveillance Study of Bacterial Contamination of the Parent's Cell Phone in the NICU
Official title: Surveillance Study of Bacterial Contamination of the Parent's Cell Phone in the NICU and the Effectiveness of an Antimicrobial Gel in Reducing Transmission to the Hands
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Bacterial Contamination Rate of the Cell Phones
Keywords: bacterial contamination
Lead sponsor: Pediatrix
Sponsor class: OTHER
First posted: 2012-03-22
Enrollment: 50
Sex: ALL
Minimum age (years): 13
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Parent's that have a cell phone when visiting their child in the NICU.

Brief summary: The purpose of this study is to determine the contamination rate of the parents cell phone in a newborn intensive care setting and identify the types of bacteria contaminating the cell phone as well as evaluating the effectiveness of an antimicrobial gel in reducing the transmission of bacteria from the cell phone to the parents hands.

Detailed description: J Perinatol. 2013 Dec;33(12):960-3. doi: 10.1038/jp.2013.108. Epub 2013 Sep 5.

Eligibility criteria: Inclusion Criteria:

* Parents with a cell phone

Exclusion Criteria:

* Parents that do not have a cell phone

Primary outcomes:
measure: Determine contamination rate of parents cellphone in the NICU and identify types of bacteria on cell phones while evaluating the effectiveness of antimicrobial gel in reducing the transmission of bacteria from cellphone to parents hands.
timeFrame: contamination rate through bacterial swabs
Secondary outcomes:
Other outcomes:
Locations:
city: Seattle
country: United States
facility: Swedish Medical Center
state: Washington
Study officials:
affiliation: Swedish Hospital and Medical Center
name: Michael Kamitsuka, MD
role: PRINCIPAL_INVESTIGATOR
References: